{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:19:44Z","timestamp":1790990384011,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":1323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NCI","award":["RC4CA156551-01"],"award-info":[{"award-number":["RC4CA156551-01"]}]},{"name":"NCI","award":["R01CA169200-03"],"award-info":[{"award-number":["R01CA169200-03"]}]},{"name":"NCI","award":["R01CA142832-05"],"award-info":[{"award-number":["R01CA142832-05"]}]},{"name":"The Julie Fund"},{"name":"NCI","award":["RC4CA156551-01"],"award-info":[{"award-number":["RC4CA156551-01"]}]},{"name":"NCI","award":["R01CA169200-03"],"award-info":[{"award-number":["R01CA169200-03"]}]},{"name":"NCI","award":["R01CA142832-05"],"award-info":[{"award-number":["R01CA142832-05"]}]},{"name":"The Julie Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1093\/annonc\/mdw083","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T07:27:55Z","timestamp":1462174075000},"page":"i4-i10","source":"Crossref","is-referenced-by-count":47,"special_numbering":"S1","title":["Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"J.","family":"Krzystyniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ceppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdw083_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1093\/annonc\/mdw083_bb0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/AOG.0000000000000854","article-title":"Trends in relative survival for ovarian cancer from 1975 to 2011","volume":"125","author":"Wright","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1093\/annonc\/mdw083_bb0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ygyno.2012.12.016","article-title":"Global ovarian cancer health disparities","volume":"129","author":"Chornokur","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdw083_bb0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2009.02.009","article-title":"Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study","volume":"113","author":"Farley","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdw083_bb0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccr.2009.10.018","article-title":"A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2","volume":"16","author":"Mok","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1093\/annonc\/mdw083_bb0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2008.08.020","article-title":"Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study","volume":"111","author":"Darcy","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdw083_bb0040","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.2006.09.0795","article-title":"Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas","volume":"25","author":"Birrer","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdw083_bb0045","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1200\/JCO.2004.04.070","article-title":"Gene expression signature with independent prognostic significance in epithelial ovarian cancer","volume":"22","author":"Spentzos","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7353","key":"10.1093\/annonc\/mdw083_bb0050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"issue":"9951","key":"10.1093\/annonc\/mdw083_bb0055","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1093\/annonc\/mdw083_bb0060","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2014evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdw083_bb0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II\u2013IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1093\/annonc\/mdw083_bb0070","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1093\/annonc\/mdw083_bb0075","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdw083_bb0080","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdw083_bb0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2012.04.029","article-title":"Ovarian low-grade serous carcinoma: a comprehensive update","volume":"126","author":"Diaz-Padilla","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw083_bb0090","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas","volume":"24","author":"Gourley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdw083_bb0095","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1158\/1541-7786.MCR-08-0193","article-title":"Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors","volume":"6","author":"Anglesio","year":"2008","journal-title":"Mol Cancer Res"},{"issue":"22","key":"10.1093\/annonc\/mdw083_bb0100","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","article-title":"Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary","volume":"65","author":"Bonome","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdw083_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2010.01.006","article-title":"Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary","volume":"117","author":"May","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdw083_bb0110","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/sj.onc.1208298","article-title":"Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential","volume":"24","author":"Meinhold-Heerlein","year":"2005","journal-title":"Oncogene"},{"issue":"3","key":"10.1093\/annonc\/mdw083_bb0115","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ygyno.2012.12.009","article-title":"Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles","volume":"128","author":"May","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdw083_bb0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1093\/annonc\/mdw083_bb0125","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1200\/JCO.2015.62.4726","article-title":"Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer","volume":"33","author":"Grisham","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdw083_bb0130","first-page":"2095","article-title":"Frequent PTEN\/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors","volume":"58","author":"Obata","year":"1998","journal-title":"Cancer Res"},{"issue":"18","key":"10.1093\/annonc\/mdw083_bb0135","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdw083_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.yexmp.2013.08.004","article-title":"TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type","volume":"95","author":"Rechsteiner","year":"2013","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"10.1093\/annonc\/mdw083_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4088","article-title":"Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas","volume":"229","author":"Anglesio","year":"2013","journal-title":"J Pathol"},{"issue":"6001","key":"10.1093\/annonc\/mdw083_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"issue":"16","key":"10.1093\/annonc\/mdw083_bb0155","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdw083_bb0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2011.01.005","article-title":"Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010","volume":"121","author":"Anglesio","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdw083_bb0165","doi-asserted-by":"crossref","first-page":"e21121","DOI":"10.1371\/journal.pone.0021121","article-title":"Identification of novel therapeutic targets in microdissected clear cell ovarian cancers","volume":"6","author":"Stany","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1093\/annonc\/mdw083_bb0170","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14728214.2015.1036739","article-title":"Emerging therapies: angiogenesis inhibitors for ovarian cancer","volume":"20","author":"Jackson","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"10.1093\/annonc\/mdw083_bb0175","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am J Pathol"},{"issue":"21","key":"10.1093\/annonc\/mdw083_bb0180","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Campbell","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdw083_bb0185","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10147-010-0177-z","article-title":"Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases","volume":"16","author":"Takano","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"10.1093\/annonc\/mdw083_bb0190","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bat013","article-title":"curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome","volume":"2013","author":"Ganzfried","year":"2013","journal-title":"Database"},{"issue":"5","key":"10.1093\/annonc\/mdw083_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju048","article-title":"Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples","volume":"106","author":"Riester","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1093\/annonc\/mdw083_bb0200","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","article-title":"Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer","volume":"19","author":"Chang","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdw083_bb0205","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1172\/JCI70625","article-title":"FGF18 as a prognostic and therapeutic biomarker in ovarian cancer","volume":"123","author":"Wei","year":"2013","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1093\/annonc\/mdw083_bb0210","first-page":"357","article-title":"Immunopathogenesis of ovarian cancer","volume":"100","author":"Thompson","year":"2009","journal-title":"Minerva Med"},{"issue":"12","key":"10.1093\/annonc\/mdw083_bb0215","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","article-title":"Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice","volume":"67","author":"Robinson-Smith","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdw083_bb0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdw083_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molmed.2011.01.012","article-title":"Targeting mutant fibroblast growth factor receptors in cancer","volume":"17","author":"Greulich","year":"2011","journal-title":"Trends Mol Med"},{"issue":"178","key":"10.1093\/annonc\/mdw083_bb0230","doi-asserted-by":"crossref","first-page":"178ra39","DOI":"10.1126\/scitranslmed.3005414","article-title":"Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer","volume":"5","author":"Harding","year":"2013","journal-title":"Sci Transl Med"},{"issue":"28","key":"10.1093\/annonc\/mdw083_bb0235","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419316126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419316126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/suppl_1\/i4\/19446837\/mdw083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T08:32:14Z","timestamp":1582187534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419316126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":46,"alternative-id":["S0923753419316126"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw083","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}